American Bio Medica's oxycodone assay gains US nod:
This article was originally published in Clinica
Executive Summary
American Bio Medica Corporation has received US FDA 510(k) clearance for what it claims is the first on-site, point-of-care test for oxycodone, a synthetic opiate found in commonly abused prescription painkillers, including OxyContin. The Rapid One OXY assay is a urine-based test that can provide results within minutes. It is designed to detect oxycodone at a very low level and does not detect other opiates at this level, says the Kinderhook, New York firm.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.